Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
| Autor: | Matteo Donadon, Shadya Sara Darwish, Guido Torzilli, Daniele Del Fabbro, Fabio Procopio, Matteo Cimino, Lorenza Rimassa, Armando Santoro, Luca Viganò, Carlo Carnaghi, Nicola Personeni |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment 030230 surgery Irinotecan Disease-Free Survival Article Contraindications Procedure 03 medical and health sciences 0302 clinical medicine Risk Factors Surgical oncology Antineoplastic Combined Chemotherapy Protocols medicine Hepatectomy Humans Contraindication Survival rate Response Evaluation Criteria in Solid Tumors Aged Chemotherapy business.industry Liver Neoplasms Hazard ratio Middle Aged Magnetic Resonance Imaging Tumor Burden Surgery Bevacizumab Oxaliplatin Survival Rate Oncology Tumor progression 030220 oncology & carcinogenesis Disease Progression Female Fluorouracil Colorectal Neoplasms Tomography X-Ray Computed business |
| Zdroj: | Annals of Surgical Oncology. 25:1676-1685 |
| ISSN: | 1534-4681 1068-9265 |
| Popis: | Not all patients with resectable colorectal liver metastases (CLM) benefit from liver resection (LR); only patients with disease progression during chemotherapy are excluded from surgery. This study was performed to determine whether tumor behavior (stable disease/progression) from the end of chemotherapy to LR impacts prognosis. Patients undergoing LR after tumor response or stabilization during chemotherapy were considered. Overall, 128 patients who underwent examination by two imaging modalities (computed tomography/magnetic resonance imaging) after chemotherapy with a > 3-week interval between the two imaging modalities were analyzed. Any variation in CLM size was registered. Tumor progression was defined according to the response evaluation criteria in solid tumors (RECIST) criteria. Among 128 patients with stable disease or partial response to preoperative chemotherapy, 32 (25%) developed disease progression in the chemotherapy to LR interval, with a disease progression rate of 17% when this interval was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink